Trazodone

Indications & formulation #

Major depressive disorder in adults; not an insomnia dosing recommendation. This reference covers the selected formulation; other indications and products need their own evidence.

Dose reference #

Adult educational reference · Oral immediate-release tablet · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.

Selected label: start 150 mg/day divided; increase by 50 mg/day every 3–4 days if appropriate. Outpatient maximum 400 mg/day; inpatient maximum 600 mg/day.

Contraindications & important cautions #

Avoid MAOIs. Priapism, orthostasis, arrhythmia and serotonin toxicity require explicit counseling.

Selected important cautions; consult the full product information for all contraindications and warnings.

Adverse effects #

Sedation, orthostasis, cardiac concerns and priapism require counseling appropriate to the product.

Interactions #

Review additive sedation, serotonergic combinations, QT-related risk and metabolic modifiers.

Monitoring #

Clarify indication, formulation and daytime impairment; review falls, orthostasis and relevant cardiac context.

Special populations #

Renal/hepatic impairment has limited study; use caution. CYP3A4 inhibitors/inducers may require dose modification.

Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.

Discontinuation, restarting & counseling #

Taper; take shortly after food and review daytime sedation and falls.

Brands & products #

Reference coverage #

Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.